CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01009593
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:16.283680+00:00
Published At: 2012-09-10T00:00:00+00:00
Record Updated At: 2012-09-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent", "Carcinoma, Hepatocellular", "Liver Diseases", "Neoplasms by Histologic Type", "Digestive System Neoplasms", "Carcinoma", "Liver Neoplasms", "Neoplasms", "Neoplasms by Site", "Digestive System Diseases", "Adenocarcinoma", "Neoplasms, Glandular and Epithelial"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2012-09-10"
protocolSection.identificationModule.nctId: "NCT01009593"
protocolSection.identificationModule.officialTitle: "An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.